Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including:
New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral Production System
Novel gene editing tools for primary T cells
Biotechnology
Medicine
Gene Editing
Crispr-Cas9
Cell Culture
Cancer Research
Stem Cell Technologies
Neuroscience
Gene Expression
Developmental Biology
Cell Signaling / Transduction
Cancer Therapeutics
Brain
Assay Development
Oncology
Asia50%
North America33%
Europe17%
Website Visitors100%
Research Scientist40%
Clinical Laboratory Scientist20%
Marketing/Sales20%
Lab Management20%
Clinical Laboratory17%
Biotech Company17%
Medical School17%
Other17%